COVID-19 positivity ratio declines in Pakistan, recorded at 1.69%

COVID-19 positivity ratio declines in Pakistan, recorded at 1.69%

Coronavirus inspiration proportion decreases in Pakistan, recorded at 1.69%

According to data released by the National Command and Operation Centre (NCOC), 27 more people succumbed to the disease during this period, taking the nationwide death toll to 22,034.

Pakistan keeps on recording a steady decrease in new COVID-related new diseases and energy rate.

As indicated by the National Command and Operation Center (NCOC) information, 3,084 new diseases arose when 38,883 examples were tried during a similar period. The inspiration pace of new cases after a decay was recorded at 7.93%, the NCOC said.

During the previous 24 hours, upwards of 113 individuals lost their lives to the pandemic, taking the general loss of life to 19,106.

ISLAMABAD: Pakistan continues to record a decline in COVID-19-related deaths and new cases, as the country recorded 1.69% positivity rate over the past 24 hours.

Pakistan recorded COVID-19 energy pace of 1.69 percent as of the absolute 39,017 examples tried for the presence of the contamination, 663 were announced positive. This brings the complete number of affirmed cases in the country to 949,784.

With 1,204 individuals getting their wellbeing back during the previous 24 hours, the general number of the recuperated remains at 894,352. Since the episode of the pandemic, the nation has done 14,187,441 tests to analyze the dangerous infection.

Read more: Antibody drug reduces hospitalization, death in COVID-19 patients

GlaxoSmithKline and Vir Biotechnology said on Monday final results from a late-stage study of their monoclonal antibody confirmed it significantly reduced hospitalization and death among high-risk COVID-19 patients when given early in the disease.

The treatment, sotrovimab, received an emergency use authorization from the U.S. Food and Drug Administration in May, while the European Union’s drug regulator has also backed it. read more

The drugmakers also said on Monday the U.S. National Institutes of Health (NIH) has recommended sotrovimab to treat high-risk, non-hospitalized patients with mild-to-moderate COVID-19.

Article